News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Mariano Provencio: Perioperative chemotherapy and nivolumab in NSCLC
Oct 18, 2024, 19:52

Mariano Provencio: Perioperative chemotherapy and nivolumab in NSCLC

Mariano Provencio, Medical Oncology Chair at University Hospital Puerta de Hierro, shared on X:

”With NADIM at Spanish Lung Cancer Group (Grupo Español de Cáncer de Pulmón), we were disruptive. We had to overcome skepticism to break the standard.

Today, 5 years later, The Lancet Oncology confirms the robustness of our strategy. 69% alive at 5Y, without severe toxicities. Congratulations.”

Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial

Authors: Mariano Provencio, Ernest Nadal, Amelia Insa, Rosario García Campelo, Joaquín Casal, Manuel Dómine, Bartomeu Massuti, Margarita Majem, Delvys Rodríguez-Abreu, Alex Martínez-Martí, Javier de Castro, David Gómez de Antonio, Iván Macia, Santiago Figueroa, Luís Fernández Vago, Virginia Calvo, Ramón Palmero, Belén Sierra-Rodero, Cristina Martínez-Toledo, Marta Molina-Alejandre, Roberto Serna-Blasco, Atocha Romero, Alberto Cruz-Bermúdez.

Mariano Provencio: Perioperative chemotherapy and nivolumab in NSCLC

Alberto Cruz-Bermúdez. Alex Martínez-Martí Amelia Insa Atocha Romero Bartomeu Massuti Belén Sierra-Rodero cancer Cristina Martínez-Toledo David Gómez de Antonio Delvys Rodriguez Abreu Ernest Nadal Grupo Español de Cáncer de Pulmón Iván Macia Javier de Castro Joaquín Casal Luís Fernández Vago Lung cancer M. Provencio Manuel Dómine Margarita Majem Mariano Provencio Marta Molina-Alejandre nivolumab OncoDaily Oncology Perioperative Chemotherapy Ramón Palmero Roberto Serna-Blasco Rosario García-Campelo Santiago Figueroa The Lancet Oncology Virginia Calvo
Special Coverage
Insight
Nov 13, 2024, 08:51
Reporting pharmacogenetic variants and cancer WGS data could guide safer prescribing
Blog
Nov 13, 2024, 08:49
Yüksel Ürün: Promising findings on SGLT2 as a biomarker for papillary RCC by Erman Akkus
Blog
Nov 13, 2024, 08:46
Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer
Blog
Nov 13, 2024, 08:39
Eva Blondeaux on safety of pregnancy in BRCA carriers
Blog
Nov 13, 2024, 08:39
What can cancer in ferrets, opossums, and even penguins teach us about cancer in humans - AACR
Blog
Nov 13, 2024, 08:36
Research Is The Reason Nicole Seagriff had options to treat her breast cancer - The Breast Cancer Research Foundation
Blog
Nov 13, 2024, 08:30
Patrick Hwu: Exploring the unique partnership between Moffitt Cancer Center and Iovance Biotherapeutics
Insight
Nov 13, 2024, 08:27
Paolo Tarantino: The promise and challenges of response-adapted trials in breast oncology
Insight
Nov 13, 2024, 07:41
Key Factors in Menstrual Recovery for Pre-menopausal Breast Cancer on Tamoxifen
Insight
Nov 13, 2024, 07:12
Luigi Lorini was awarded the 2024 Martin "Mac" Cheever Excellence in Clinical Trial Design Travel Award for Immunoprevention
Blog
Nov 12, 2024, 23:10
Hesham ElGhazaly: Empowering Women’s Health Through Solidarity
Blog
Nov 12, 2024, 23:07
Helen’s Journey with Breast Cancer - The Max Foundation